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Building momentum for malaria vaccine 
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Abstract 
To maintain momentum towards improved malaria control and elimination, a vaccine would be a key addition to the 
intervention toolkit. Two approaches are recommended: (1) promote the development and short to medium term 
deployment of first generation vaccine candidates and (2) support innovation and discovery to identify and develop 
highly effective, long-lasting and affordable next generation malaria vaccines.
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Background
In what is a truly great public health success story, 
expanded efforts to control and eliminate malaria have 
effectively halved malaria incidence and mortality since 
2000. Several million lives have been saved in that time 
and a number of previously endemic countries in Asia, 
South and Central America and Africa have been for-
mally declared malaria free.
This astonishing success has been achieved with a 
limited toolkit, largely comprising methods to prevent 
transmission by the mosquito vector through the use of 
insecticide-treated bed nets and indoor residual spray-
ing, the use of chemoprevention in specific, vulner-
able groups, and effective chemotherapy following rapid 
point-of-care diagnosis. Current vector control and 
effective anti-malarial treatment strategies represent sig-
nificant success in both product development and imple-
mentation science.
However, progress in areas with high transmission has 
slowed and further reduction in malaria incidence and 
deaths has stalled in recent years. The 2018 and 2019, 
World Health Organization (WHO) World Malaria 
Reports documented a global increase in the number of 
malaria cases. Despite some countries achieving elimina-
tion, malaria increased in both the 10 most highly bur-
dened countries and 11 of the 21 countries earmarked for 
elimination by 2020 [1].
A number of daunting realities impact on the poten-
tial for substantial further progress. These include: (1) 
malaria remains a staggeringly large human health prob-
lem with 1,200 malaria deaths every day, (2) longitudinal 
tracking of the effective implementation of existing tools 
show imperfect outcomes and suggests that existing tools 
may be insufficient to control malaria in high-transmis-
sion settings, no matter how well they are applied, (3) 
shifts in climate, population growth and movement, and 
changes in the location and species of vector, threaten 
to introduce malaria into new settings (for example, 
greater urban transmission in Africa by Anopheles ste-
phensi), (4) problems achieving high coverage of cur-
rent interventions are exacerbated by the emergence of 
vectors resistant to insecticides, parasites resistant to 
first-line treatment and parasite strains that evade diag-
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parasite biology and ecology tell us that resurgence can 
be rapid and devastating if public health measures fail or 
are not maintained, and (6) the COVID-19 pandemic has 
exposed the vulnerability of global supply chains and the 
health systems in many malaria endemic settings. Hard 
won gains can rapidly be lost.
Main text
New interventions are needed to reignite the fight against 
malaria. As for other infectious diseases, vaccines have 
the potential to impact burden in a cost-effective way and 
may, in the long term, contribute to the goal of malaria 
eradication. The feasibility of vaccine-induced protec-
tion against malaria has been demonstrated [2], but the 
development of malaria vaccines requires the vigorous 
and sustained engagement of many stakeholders. Recent 
advances in the understanding of malaria parasite biol-
ogy, vaccinology and passive immunization approaches, 
suggest that the next advance in malaria vaccines is 
within reach─but only with sustained research and 
development efforts.
The WHO reconvened the Malaria Vaccine Advisory 
Committee (MALVAC) in 2019, and organized a stake-
holder consultation about the state-of-the-art in malaria 
vaccine development [Vekemans et  al. pers. commun.]. 
MALVAC’s mandate is to provide guidance on research 
priorities for the development of new malaria vaccines. 
Detailed WHO perspectives on the medical need and 
research priorities in malaria vaccine R&D will emerge 
over the next 12–24 months, but consultations and MAL-
VAC discussions led to the recognition of the need to 
advance in parallel two distinct strategies:
1. To support continued engagement to ensure the 
availability of 1st and 2nd generation vaccine candi-
dates with moderate efficacy, that show potential for 
widespread use in the next 3–10 years.
2. To support innovation and stimulate the discovery 
of next generation, highly protective and long-lasting 
malaria vaccines; for this to succeed, identifying effi-
cient and cost-effective clinical development, financ-
ing and regulatory pathways will be key. Lessons can 
no doubt be learnt from the accelerated develop-
ment pathways and approaches being developed for 
COVID-19 vaccines.
1st Generation Vaccines with partial protection—an 
important addition to the intervention toolkit
The most advanced malaria vaccine is RTS,S/AS01, devel-
oped by Glaxo Smith Kline with support from the Bill 
and Melinda Gates Foundation, the Walter Reed Army 
Institute of Research and PATH, and the collaboration 
of a large number of African and other international 
research institutions. RTS,S/AS01 targets Plasmodium 
falciparum sporozoites and demonstrated an efficacy of 
39% over 4  years against malaria incidence in Phase III 
trials in African children aged 5–17 months at the time 
of dose 1 [3]. This moderate efficacy, documented in 
the context of high mosquito net use and similar to the 
level of protection afforded by well-implemented vec-
tor control, is potentially valuable to complement exist-
ing strategies for the reduction of malaria disease and 
death among young children in endemic areas. RTS,S/
AS01 pilot implementation is ongoing in three malaria 
endemic countries—Ghana, Malawi and Kenya [4]. In 
addition to consolidating the vaccine’s safety profile, the 
pilot implementation will generate data on its survival 
impact and test the feasibility of delivering the four-dose 
RTS,S/AS01 regimen under routine conditions. Results 
of the implementation studies are keenly awaited and will 
be used to guide policy recommendations on the roll out 
of RTS,S/AS01 in malaria endemic countries.
RTS,S/AS01 has demonstrated the feasibility of devel-
oping a malaria vaccine and has laid down a clinical 
development path for future vaccines. Its use in pro-
grammatic contexts will inform our understanding of the 
potential value of malaria vaccines in combination with 
other tools for malaria control and elimination.
In addition to RTS,S/AS01, R21/Matrix-M, an RTS,S-
like vaccine, is one of several potential second generation 
vaccines and is currently being tested for efficacy in the 
field. Notwithstanding enormous technical and practi-
cal challenges, the radiation-attenuated sporozoite vac-
cine, PfSPZ, has undergone extensive testing including 
in endemic African countries. Although high efficacy has 
been demonstrated in adults under experimental chal-
lenge conditions, efficacy in naturally exposed children 
is considerably lower, warranting further improvements. 
Progress is also being made through the evaluation of 
Rh5, a promising P. falciparum blood stage vaccine can-
didate, although it will be necessary to achieve higher 
rates of growth inhibition for such vaccines to yield clini-
cally relevant efficacy.
The evaluation of sexual-stage candidates continues, 
and new tools to test vaccines designed to interrupt 
man-to mosquito transmission are being developed. 
Subunit vaccines that combine multiple antigens from 
the pre-erythrocytic and blood stages could synergize 
immune responses and yield higher efficacy. The addi-
tion of sexual-stage antigens to these vaccines could 
potentially enhance their impact on malaria transmis-
sion [2]. Continued investment in the development of 
these approaches is warranted given the progress to 
date and the scale of their potential impact on public 
health. In addition to subunit vaccines, innovations in the 
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development of whole organism attenuated sporozoite 
vaccines are needed to develop formulations and delivery 
strategies that facilitate programmatic implementation in 
endemic countries.
Future malaria vaccines–towards highly efficacious, 
long‑lasting vaccines and a more streamlined 
development pathway
Malaria vaccines that confer long-term, robust protec-
tion, that are inexpensive and relatively simple to deploy, 
are not on the short-term horizon. To accelerate progress 
in the development of such vaccines, a deliberate stra-
tegic pivot to fundamental discovery science is needed. 
Breakthrough science, with possibly unconventional 
approaches, will be required to meet these ambitious 
goals [5].
Decoding of the malaria parasite genome together 
with functional studies using molecular genetic tools, 
whole genome approaches as well as classical biochem-
istry and cell biology, are helping unravel the complex 
biology of the malaria parasite. Advances in understand-
ing how malaria parasites interact with the human host 
and its immune system should enable new strategies to 
target the parasite at different stages with novel vaccine 
approaches. Advances in our understanding of basic 
human immunology and powerful new tools that enable 
dissection of immune responses at a systems level need 
to be brought to bear on malaria. Other advances such as 
structural vaccinology can provide unique insights into 
the molecular basis of protective antibody responses that 
could lead to therapeutic or prophylactic monoclonal 
antibodies and inform optimization of vaccine antigens 
to achieve higher efficacy.
Conclusion
The development of vaccines against parasitic diseases is 
complex and difficult due to the long history of co-evo-
lution of parasites with their hosts. Malaria vaccines are 
currently envisioned as complementary tools to be added 
to the core package of interventions. However, the pro-
gress made in understanding malaria parasite biology 
and pathogenesis, as well as both basic and technological 
advances in human immunology and vaccinology, means 
the time is right to attempt the development of malaria 
vaccines with high efficacy. It is time to deepen and 
expand our ambitions at all levels, basic and translational, 
to develop future malaria vaccines that are game chang-
ers in efforts to eliminate malaria and create a pathway 
for other parasitic diseases. A highly efficacious malaria 
vaccine remains an ambitious target, but with commit-
ment of necessary resources, it is more within reach 
today than ever before.
Abbreviations




Chetan E. Chitnis, Edwin J. Asturias, Philip Bejon, Katharine A. Collins, 
Brendan S. Crabb, Socrates Herrera, Miriam Laufer, N. Regina Rabinovich, 
Meta Roestenberg, Adelaide Shearley, Halidou Tinto and Marian Wentworth 
Members of the Malaria Vaccine WHO Advisory Committee (MALVAC).
Disclaimer
The opinions expressed herein are those of the authors and do not neces-
sarily reflect the views and decisions of the World Health Organization.
Authors’ contributions
All authors contributed to the writing, read and approved the final 
manuscript.
Funding
WHO is supported financially by the Bill and Melinda Gates foundation for 
malaria vaccine development-related work. The funder played no role in 
the present manuscript.
Availability of data and materials
Not applicable.





KAC is a malaria vaccine patent holder. All authors report institutional fund-
ing for malaria or vaccine-related research activities.
Author details
1 Institut Pasteur, Paris, France. 2 World Health Organization, Geneva, 
Switzerland. 3 University of Colorado School of Medicine and Colorado 
School of Public Health, Denver, USA. 4 KEMRI-Wellcome Trust Research 
Programme, Kilifi, Kenya. 5 Department of Medical Microbiology, Radboud 
University Medical Center, Nijmegen, The Netherlands. 6 Burnet Institute, 
Melbourne, Australia. 7 Consorcio Para La Investigacion Cientifica, Cali, 
Colombia. 8 University of Maryland School of Medicine, Baltimore, USA. 
9 IS Global, Barcelona, Spain. 10 Harvard TH Chan School of Public Health, 
Boston, USA. 11 Leiden University Medical Center, Leiden, The Netherlands. 
12 John Snow Inc, Research & Training Institute, Boston, USA. 13 Institut de 
Recherche en Sciences de La Santé, Ouagadougou, Burkina Faso. 14 Man-
agement Sciences for Health, Arlington, USA. 
Received: 31 August 2020   Accepted: 11 November 2020
References
 1. WHO. World Malaria Report, 2019. Geneva, World Health Organization, 
2019. https ://www.who.int/publi catio ns-detai l/world -malar ia-repor 
t-2019
 2. Laurens MB. The promise of a malaria vaccine-are we closer? Annu Rev 
Microbiol. 2018;72:273–92.
 3. Vandoolaeghe P, Schuerman L. The RTS, S/AS01 malaria vaccine in 
children 5 to 17 months of age at first vaccination. Exp Rev Vaccines. 
2016;15:1481–93.
 4. WHO. The Malaria Vaccine Implementation Programme. 2020 Geneva, 
World Health Organization, 2020 March. https ://www.who.int/immun 
izati on/disea ses/malar ia/malar ia_vacci ne_imple menta tion_progr 
amme/en/
Page 4 of 4Chitnis et al. Malar J          (2020) 19:421 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 5. The malERA Refresh Consultative Panel on Basic Science and Enabling 
Technologies. malERA: An updated research agenda for basic science 
and enabling technologies in malaria elimination and eradication. 
PLoS Med 2017;14:e1002451.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
